Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Afrocentric InvestmentJSE:ACT 52 EV-to-EBIT is -1.78 as of Jul. 18, 2026. GuruFocus rates JSE:ACT with a GF Score™ of 52/100 and a GF Value™ of R2.07 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 470 Healthcare Providers & Services companies, Afrocentric Investment ranks worse than 212765.74% on this metric.
The historical rank and industry rank for Afrocentric Investment's EV-to-EBIT or its related term are showing as below:
JSE:ACT'
s EV-to-EBIT Range Over the Past 10 Years
Min: -3.09 Med: 6.17 Max: 13.33
Current: -1.78
During the past 13 years, the highest EV-to-EBIT of Afrocentric Investment was 13.33. The lowest was -3.09. And the median was 6.17.
JSE:ACT's EV-to-EBIT is ranked worse than 100% of 470
companies
in the Healthcare Providers & Services industry
Industry Median: 15.72
vs JSE:ACT: -1.78
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Afrocentric Investment's Enterprise Value for the quarter that ended in Dec. 2025 was R1,245 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Afrocentric Investment's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was R-456 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Afrocentric Investment's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Afrocentric Investment EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Afrocentric Investment's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Afrocentric Investment's EV-to-EBIT falls into.
Afrocentric Investment's current Enterprise Value is R812 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Afrocentric Investment's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was R-456 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Afrocentric Investment (JSE:ACT) has a EV-to-EBIT of -1.78 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Afrocentric Investment and its competitors. According to the industry distribution chart, Afrocentric Investment ranks #999999 out of 470 companies in the Healthcare Providers & Services industry.
Is Afrocentric Investment's EV-to-EBIT too high?
Afrocentric Investment's current EV-to-EBIT is -1.78. Based on the distribution chart, Afrocentric Investment ranks #999999 out of 470 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Afrocentric Investment has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Afrocentric Investment's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Afrocentric Investment ranks #999999 out of 470 companies for EV-to-EBIT. This places Afrocentric Investment in the lower half of its industry. The industry median EV-to-EBIT is 15.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.72, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Afrocentric Investment and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Afrocentric Investment's current EV-to-EBIT is -1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Afrocentric Investment stock overvalued right now?
Based on GuruFocus' analysis, Afrocentric Investment (JSE:ACT) is currently considered Possible Value Trap. The stock's GF Value™ is R2.07, compared to a current price of R0.80 — trading 61.4% below its estimated fair value. The current EV-to-EBIT is -1.78. Afrocentric Investment's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Afrocentric Investment (JSE:ACT), the current EV-to-EBIT is -1.78 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Afrocentric Investment (JSE:ACT) Overvalued in 2026?
Based on GuruFocus' analysis, Afrocentric Investment stock appears to be undervalued.
The current stock price of R0.80 is trading 61.4% below its estimated GF Value™ of R2.07.
GuruFocus considers Afrocentric Investment to be Possible Value Trap.
Key valuation signals for JSE:ACT:
EV-to-EBIT: -1.78
GF Value™: R2.07 vs. price of R0.80 (61.4% below fair value)
No single metric tells the full story. See the JSE:ACT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Afrocentric Investment Corp Ltd is an investment holding company providing specialised services and products to the public and private healthcare sectors. It focuses on making quality healthcare accessible and affordable to members and beneficiaries, with the principal objective of ensuring the delivery of efficient health management services and the distribution of quality products. Its business segments include Healthcare SA, comprising medical scheme administration and health risk management services; Healthcare Retail, comprising pharmaceutical sales and services; Healthcare Africa, comprising healthcare services outside South Africa in Namibia and Mauritius; and IT-related services predominantly within South Africa. It operates across South Africa, Botswana, Mauritius, and Namibia.
52GF Score
Get the complete analysis for JSE:ACT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:ACT has been successfully added to your 
